AU7467898A - Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy - Google Patents

Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy

Info

Publication number
AU7467898A
AU7467898A AU74678/98A AU7467898A AU7467898A AU 7467898 A AU7467898 A AU 7467898A AU 74678/98 A AU74678/98 A AU 74678/98A AU 7467898 A AU7467898 A AU 7467898A AU 7467898 A AU7467898 A AU 7467898A
Authority
AU
Australia
Prior art keywords
partial
signal
monoclonal antibodies
binding anti
clonal anergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74678/98A
Inventor
Jeffrey A Bluestone
Marcus R Clark
Michael S. Cole
Judith A. Smith
J. Yun Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of AU7467898A publication Critical patent/AU7467898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU74678/98A 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy Abandoned AU7467898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4408497P 1997-04-21 1997-04-21
US60044084 1997-04-21
PCT/US1998/008029 WO1998047531A2 (en) 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy

Publications (1)

Publication Number Publication Date
AU7467898A true AU7467898A (en) 1998-11-13

Family

ID=21930444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74678/98A Abandoned AU7467898A (en) 1997-04-21 1998-04-21 Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy

Country Status (2)

Country Link
AU (1) AU7467898A (en)
WO (1) WO1998047531A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
ES2559763T3 (en) 2002-09-10 2016-02-15 Affimed Gmbh CD3 specific human antibody with immunosuppressive properties
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1613273B1 (en) * 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
CN1871259A (en) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 Improved antibodies having altered effector function and methods for making the same
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
SI1716178T1 (en) * 2004-02-16 2010-11-30 Micromet Ag Less immunogenic binding molecules
CZ200755A3 (en) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Anti-CD154 antibody peptides
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP3101033B1 (en) 2006-01-12 2019-01-02 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
US9056906B2 (en) 2006-06-14 2015-06-16 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2668411C (en) 2006-11-02 2020-02-25 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
MX2009010120A (en) 2007-03-22 2009-10-19 Ucb Pharma Sa Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof.
WO2008137500A2 (en) * 2007-05-01 2008-11-13 The Brigham And Women's Hospital Immunosuppression with antibody against itm2a
EP2185594B1 (en) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
KR20100126811A (en) * 2008-03-14 2010-12-02 바이오콘 리미티드 A monoclonal antibody and a method thereof
KR20210113446A (en) 2008-05-02 2021-09-15 악셀레론 파마 인코포레이티드 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
EP2523976B1 (en) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
CN105963694B (en) 2010-04-30 2019-11-05 阿雷克森制药公司 Anti- C5A antibody and the method for using the antibody
JP2013533243A (en) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート Antibody to C3d fragment of complement component 3
JP6150734B2 (en) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド Use of anti-CD200 antibodies to prolong allograft survival
WO2012145539A1 (en) 2011-04-20 2012-10-26 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
JP6530391B2 (en) 2013-07-23 2019-06-12 バイオコン・リミテッド Use of a CD6 Binding Partner and Methods Based Thereon
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
AU2014339898B2 (en) 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
CN108348578B (en) 2015-08-04 2022-08-09 阿塞勒隆制药公司 Methods for treating myeloproliferative disorders
WO2018073734A1 (en) 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
ES2948647T3 (en) 2017-05-04 2023-09-15 Acceleron Pharma Inc TGF-beta type II receptor fusion proteins and uses thereof
DK3658184T3 (en) 2017-07-27 2023-11-27 Alexion Pharma Inc HIGHLY CONCENTRATED ANTI-C5 ANTIBODY FORMULATIONS
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
BR112022021450A2 (en) 2020-04-24 2022-12-27 Millennium Pharm Inc CD19 OR LEADING FRAGMENT, METHOD OF TREATMENT OF A CANCER, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID, VECTOR AND, ISOLATED CELL
JP2024515066A (en) 2021-04-09 2024-04-04 武田薬品工業株式会社 Antibodies targeting complement factor D and uses thereof
WO2022221767A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
EP4330284A2 (en) 2021-04-26 2024-03-06 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
MX2023011712A (en) 2021-04-26 2023-10-12 Millennium Pharm Inc Anti-adgre2 antibodies and uses thereof.
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same

Also Published As

Publication number Publication date
WO1998047531A2 (en) 1998-10-29
WO1998047531A3 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
AU7467898A (en) Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
IL128406A0 (en) Monoclonal antibodies
AU7967294A (en) A monoclonal anti-human il-6 receptor antibody
AU1704099A (en) Monoclonal human natural antibodies
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
HUP0003513A3 (en) Monoclonal antibody inducing apoptosis
NZ310847A (en) High affinity human monoclonal antibodies specific for rsv fusion protein
AU5958996A (en) Monoclonal antibodies for human mesenchymal stem cells
AU1462300A (en) Human pan-hcv human monoclonal antibodies
IL115232A0 (en) Monoclonal antibodies against colon carcinoma-associated antigens
AU2329897A (en) Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof
IL175399A (en) Antibodies binding to ob receptor variants
AU7576096A (en) Il-13 receptor polypeptide
EP0870826A4 (en) Novel protein and monoclonal antibody specific thereto
AU1687500A (en) Antihuman vegf monoclonal antibody
AU4752696A (en) Monoclonal antibodies for human osteogenic cell surface antigens
EP1030910A4 (en) Anti-cocaine catalytic antibody
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
EP1001020A4 (en) Antihuman pre-b cell receptor antibodies
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
AU5937598A (en) Humanized anti-human Fas antibody
PT725504E (en) RECEIVER RADIO WITH DEVICE FOR PRESENTATION OF RECEIVED DIGITAL TRANSIT INFORMATION

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase